 Brooklyn ImmunoTherapeutics Inc NYSE: BTX has announced a publication in Breast Cancer Research, which demonstrates how multiplex immunofluorescence mIF may be used to characterize the immunological activity of IRX-2 in early-stage breast cancer. IRX-2 is an allogeneic, cell-derived biologic with multiple active cytokine components, including IL-2, that act on various parts of the immune system associated with activation of the entire tumor microenvironment. 